uploads/2018/10/Emend.png

A Performance Review of Merck’s Oncology Business

By

Updated

Emend’s revenue trends

Merck & Co.’s (MRK) Emend generated revenues of $123 million in the third quarter compared to $137 million in the third quarter of 2017, reflecting a ~10% YoY (year-over-year) decline and a ~17% sequential decline.

In the US and international markets, Emend generated revenues of $71 million and $52 million, respectively, in the third quarter. That compares to $88 million and $49 million, respectively, in the same period of 2017, reflecting a ~20% YoY decline and a ~6% YoY growth, respectively.

Emend’s net revenues totaled $396 million for the first nine months of the year compared to $413 million in the same period of 2017, reflecting a ~4% YoY decline.

Article continues below advertisement

Temodar’s revenue trends

Merck’s (MRK) Temodar generated revenues of $46 million in the third quarter compared to $68 million in the third quarter of 2017, which was a ~32% YoY decline and an ~18% YoY growth, respectively.

Temodar generated revenues of $159 million in the first nine months of the year compared to $198 million in the same period of 2017, reflecting a ~20% YoY decline.

Lynparza’s and Lenvima’s revenue trends

In the third quarter, Lynparza and Lenvima generated revenues of $49 million and $43 million, respectively. In the US and international markets, Lynparza generated revenues of $33 million and $15 million, respectively, in the third quarter.

Lenvima generated revenues of $30 million and $13 million in the US and international markets, respectively, in the third quarter.

In October, the FDA granted an Orphan Drug Designation for Merck’s Lynparza for the treatment of individuals with pancreatic cancer. Merck is conducting clinical trials with Lynparza as a maintenance therapy in individuals with germline BRCA-mutated metastatic pancreatic cancer whose disease did not progress after a platinum-based therapy in the first-line setting.

Advertisement

More From Market Realist